ConvaTec Group Plc: Growth Story Outweighs Setbacks

ConvaTec Group plc ((GB:CTEC)) has held its Q4 earnings call. Read on for the main highlights of the call.

ConvaTec Group plc’s latest earnings call balanced strong financial momentum with clear operational and regulatory headwinds. Management highlighted another year of robust organic growth, rising margins, double‑digit EPS gains and powerful cash generation, underpinned by increased investment and an expanding product pipeline. Yet issues around InnovaMatrix, FDA scrutiny and inflation underscore that execution and risk management remain critical.

Consistent Organic Revenue Growth

ConvaTec has now delivered five consecutive years of organic revenue growth within its target range, reinforcing the credibility of its turnaround story. In 2025, organic growth reached 6.4% when excluding InnovaMatrix, with management noting five straight years above 5% and three above 6%, and guiding to 5%–7% organic growth in 2026 and a 6%–8% long‑term annual goal from 2027.

Operating Margin Expansion

Profitability continued to strengthen, with operating margin expanding by 110 basis points in 2025 to 22.3%, bringing cumulative expansion to 460 basis points since 2021. Management now targets at least a 23% operating margin in 2026 and is aiming for a mid‑20s level in the medium term, signaling further leverage from scale, mix and efficiency.

Double‑Digit EPS Growth and Profitability

Earnings quality improved alongside growth, as EPS rose 16% in 2025, supported by a 15% increase in net profit and 12% gains in both operating profit and EBITDA. The company expects another year of double‑digit EPS growth in 2026, pointing to continued discipline on costs as well as a richer product and geographic mix.

Strong Cash Generation and Capital Allocation

Cash generation remains a core strength, with free cash to equity reaching $362 million in 2025 and conversion at 101% under the updated definition. ConvaTec also stepped up returns to shareholders, completing a $300 million share buyback in the second half and growing its dividend by 13%, while keeping free cash flow conversion at around 100% as a target for 2026.

Increased Investment to Support Growth

To sustain and accelerate growth, ConvaTec more than doubled growth CapEx to $121 million in 2025, while holding operational CapEx steady at roughly 2.5% of sales. Management plans to continue lifting growth CapEx to expand manufacturing capacity and commercial capabilities, positioning the business to fully monetize its expanding pipeline.

Infusion Care Outperformance

Infusion Care stood out as the clear growth engine, delivering 12.5% organic growth in 2025 and further diversifying beyond diabetes. Nondiabetes therapies now represent about 15% of Infusion Care revenue, up from roughly 10% in 2024, and the company is guiding to high single‑digit growth in 2026 with scope for further acceleration as new capacity comes onstream.

Solid Performance in Continence and Ostomy Care

The core Continence and Ostomy franchises provided solid, steady contributions to the top line, with Continence Care growing 6.6% organically in 2025 and hydrophilic products accounting for more than 60% of category revenue. Ostomy Care rose 4.5%, supported by the Esteem Body product exceeding expectations and new GPO contract wins in the U.S., reinforcing ConvaTec’s competitive positioning.

Broad‑Based New Product Pipeline

Management emphasized that the current innovation slate is the broadest in the company’s history, with eight products already launched and eight more planned across 2026 and 2027. These launches are expected to be a key driver of ConvaTec’s planned acceleration to 6%–8% organic growth from 2027, supporting both top‑line expansion and mix‑driven margin gains.

InnovaMatrix Sales Collapse and Impairment

In stark contrast to the broader portfolio, InnovaMatrix suffered a sharp downturn, with sales falling by $30 million to $69 million in 2025 amid an increasingly challenging reimbursement landscape. The new CMS rate from January 2026 implies roughly an 80% price cut, prompting a $72 million non‑cash impairment, and the product is now expected to be only about $20 million of sales in 2026 and a roughly 2% revenue headwind.

FDA Warning Letter on Complaints and CAPA

Regulatory risk crystallized through an FDA warning letter focused on ConvaTec’s complaint handling and corrective and preventive action systems, including references to leakage‑related customer issues. While management stressed that no product safety issue has been identified, it acknowledged that internal processes fell short and has made remediation and quality system strengthening an immediate top priority.

Inflationary Pressure on Margins

Cost inflation remains a drag, with roughly 3% inflation in 2025 representing an estimated 110 basis point headwind to margins. Management expects similar inflation in 2026 but is leaning on price increases, productivity gains and simplification programs, which collectively contributed positive margin impact in 2025, to offset much of the pressure.

Working Capital and Net Debt Increase

Working capital rose by around $40 million in 2025, partly due to seasonality as the fourth quarter is the strongest for sales, and the company also invested more in inventory to support growth and resiliency. Net debt climbed by $272 million, but leverage was kept at the target 2x net debt‑to‑EBITDA, giving ConvaTec room to continue funding growth plans and shareholder returns.

Execution and Operational Handoffs

Management openly acknowledged that execution and cross‑functional handoffs did not always keep pace with growth and product launches, resulting in isolated back orders. These issues may have slightly constrained what growth could have been, but they also highlight clear opportunities for operational improvement and better scaling of future launches.

Salesforce Reorganization and Channel Uncertainty for InnovaMatrix

To adapt to the new economics and uncertainty around InnovaMatrix, the company reorganized its salesforce and trimmed variable commercial costs while keeping volumes stable. Nevertheless, competitor inventory, channel disruption and ongoing challenges to CMS pricing mean that any recovery will likely be uneven, with management guiding to a second‑half weighted contribution in 2026.

Regulatory and Reimbursement Risks

Beyond the FDA letter, ConvaTec flagged broader policy risks, including potential Medicare competitive bidding that could trim 1%–2% from group revenues if implemented. Additional uncertainty around tariffs and international trade rules remains, although management currently expects existing agreements, such as those stemming from the Nairobi Protocol, to continue, mitigating some of the risk.

Guidance and Forward‑Looking Outlook

Looking ahead to 2026, ConvaTec is guiding to 5%–7% organic revenue growth excluding InnovaMatrix, an operating margin of at least 23% and another year of double‑digit EPS growth, supported by strong free cash flow conversion around 100%. From 2027 onward, the company has raised its ambition to 6%–8% organic growth with mid‑20s margins and sustained double‑digit EPS growth, powered by its pipeline, capacity investments and disciplined balance sheet management.

ConvaTec’s earnings call painted a picture of a company that has moved decisively up the quality curve, with consistent growth, expanding margins and strong cash returns underpinning confidence in its medium‑term targets. While the InnovaMatrix reset, FDA scrutiny and reimbursement risks are non‑trivial, management’s candid tone, stepped‑up investment and clear financial framework suggest that, for now, the positives outweigh the headwinds for investors tracking the stock.